Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020

$3,495.00

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies.

Publication date
April 2020
Number of pages
300+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP2060

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.

 

This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2014.

 

There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.

 

Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

 

Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.

 

The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all joint venture deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.

 

Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals.

 

Chapter 4 provides a review of the leading Joint venture deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 

 

Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2014 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal.

 

The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2014. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

 

The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.

 

Key benefits

 

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of joint venture partnering deal trends since 2014
  • Analysis of the structure of joint venture agreements with numerous real life case studies
  • Comprehensive listing of all joint venture deals since 2014, together with deal terms, value and press release
  • Comprehensive access to actual joint venture contracts entered into by the world’s life science companies
  • Insight into the terms included in a joint venture agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide.         

 

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 includes:

 

  • Trends in joint venture dealmaking in the biopharma industry since 2014
  • Analysis of joint venture deal structure
  • Case studies of real-life joint venture deals
  • Comprehensive listing of joint venture deals since 2014
  • Access to joint venture contract documents
  • The leading joint venture deals by value since 2014
  • Most active joint venture dealmakers since 2014
  • The leading joint venture partnering resources

 

In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 available deals and contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

 

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

 

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive access to available contract documents for joint venture deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How are salesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 provides the reader with the following key benefits:

  • In-depth understanding of joint venture deal trends since 2014
  • Analysis of the structure of joint venture agreements with numerous real life case studies
  • Comprehensive access to over 300 joint venture deals entered into by the world’s biopharma companies, together with contract documents if available
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Identify leading joint venture deals by value since 2014
  • Identify the most active joint venture dealmakers since 2014
  • Full listing of joint venture deals by company A-Z, headline value, phase of development, deal type, therapy and technology focus

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in joint venture partnerships

 

2.1. Introduction

2.2. Definition of joint venture deals

2.3. Success factors for joint venture partnerships

2.4. When joint venture partnerships can be useful

2.5. Attributes of joint venture partnerships

2.6. Aligning partners to make the joint venture work

2.7. Trends in joint venture partnerships since 2014

2.7.1. Joint venture dealmaking by year, 2014 to 2020

2.7.2. Joint venture dealmaking by stage of development 2014 to 2020

2.7.3. Joint venture dealmaking by industry sector 2014 to 2020

2.7.4. Joint venture dealmaking by therapy area, 2014 to 2020

2.7.5. Joint venture dealmaking by technology type, 2014 to 2020

2.7.6. Joint venture dealmaking by most active company, 2014 to 2020

2.8. The future of joint venture partnerships

 

Chapter 3 – Overview of joint venture deal structure

 

3.1. Introduction

3.2. Joint venture agreement structure

3.3. Example joint venture agreements

3.3.1. Case study 1: Agila Specialties - Pfenex

3.3.2. Case study 2: Dance Biopharm – Harmony Asset

 

Chapter 4 – Leading joint venture deals

 

4.1. Introduction

4.2. Top joint venture deals by value

 

Chapter 5 - Top 25 most active active joint venture dealmakers

 

5.1. Introduction

5.2. Top 25 most active joint venture dealmakers

 

Chapter 6 – Joint venture deals including contracts directory

 

6.1. Introduction

6.2. Joint venture deals with contracts 2014 to 2020

 

Appendices

 

Appendix 1 – Joint venture dealmaking by companies A-Z

Appendix 2 – Joint venture dealmaking by industry sector

Appendix 3 – Joint venture dealmaking by stage of development

Appendix 4 – Joint venture dealmaking by therapy area

Appendix 5 – Joint venture dealmaking by technology type

Appendix 6 – Joint venture references

Appendix 7 – Resources

Appendix 8 – Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

TABLE OF FIGURES

 

Figure 1: Definition of joint venture

Figure 2: Situations where joint venture partnerships can prove useful

Figure 3: Key components of a joint venture partnership

Figure 4: Issues in implementing joint venture partnership agreements

Figure 5: Trends in joint venture deal announcements, 2014 - 2020

Figure 6: Joint venture deals signed at each phase of development, 2014 - 2020

Figure 7: Joint venture deals by industry sector, 2014 to 2020

Figure 8: Joint venture deals by therapy area, 2014 to 2020

Figure 9: Joint venture deals by technology type, 2014 to 2020

Figure 10: Top 25 most active joint venture dealmakers, 2014 to 2020

Figure 11: Joint venture shareholder agreements – what should a contract include?

Figure 12: Components of the joint venture deal structure

Figure 13: Top joint venture deals by value since 2014

Figure 14: Most active joint venture dealmakers 2014 to 2020

Figure 15: Online partnering resources

Figure 16: Deal type definitions

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3SBio, 1717 Life Science Ventures, A*STAR Agency for Science, Technology and Research, A*STAR Institute of Microelectronics (IME), A*STAR’ Institute of Molecular and Cell Biology, A2A Pharmaceuticals, AAP Implantate AG, Abbott Laboratories, Abbvie, Abilita Bio, ABIVAX, Abzena, Accellix, Accuray, Acnos Pharma, Adept Neuro, Adisseo, Advanced Prenatal Therapeutics, Advanced Technologies Solutions, Aequus Pharmaceuticals, Agilis Biotherapeutics, AgonOx, AirWare Labs, Aitbiotech, Akers Biosciences, AKESOgen, Aleafia Health, Aleva Neurotherapeutics, Allied-Bristol Life Sciences, Allied Minds, Ally Bridge Group, Altus Formulation, Alzheimer's Association, Alzheimer's Research UK, Amarantus BioSciences, Amendia, American Diabetes Association, AmerisourceBergen, Amunix, Amyris, AnaBios, Anokion, Antitope, Antoxerene, Apax Partners, Aphria, Arbele, Arbutus, ARCH Personalized Medicine Initiative, Aridis Pharmaceuticals, Aruvant Sciences, Arvinas, Ascendance Biotechnology, Ascendis Pharma, Asklepios Biopharmaceutical, Aslan Pharma, Astellas Pharma, AstraZeneca, ATAI Life Sciences, Athenex, ATL Technology, Atomwise, Atrapos Therapeutics, Atropos Therapeutics, Auramedi Farmaceutica, Autobio Diagnostics, AUT Roche Diagnostics Laboratory, AUT University, Auxly Cannabis Group, Avacta, Avactis Biosciences, Avalon GloboCare, Avivagen, Avvinity Therapeutics, Axis Therapeutics, Bain Capital, Baxter International, Bayer, Baylor College of Medicine, Baylor Miraca Genetics Laboratories, B Braun, B Braun CeGaT, Beckley Canopy Therapeutics, Beckley Foundation, Becton Dickinson, BeiGene, Beijing Genomics Institute (BGI), Beijing Leadman Biochemistry, Berry Genomics, Betaliq, BevCanna, BGI Tech Solutions, BHB Therapeutics, Bill and Melinda Gates Foundation, Bio-Techne, BioAmber, Biodist, Biodyne USA, BioFields, Biogen, Biohealth Innovation, BioHeart, BioLife Solutions, BioLight, BiolineRX, biologistex CCM, BioMed X Innovation Center, Biomerics, BioMotiv, BioPharma Services, Blackstone, Blockshine Technology, Bloomage BioTechnology, Bloom Burton, BLP Management, Blueberries Medical, Boehringer Ingelheim, Breakthrough Diagnostics, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Buchang Pharmaceutical, Buck Institute for Age Research, Bukwang Pharmaceuticals, Button Capital, Calysta Energy, Cancer Research Technology, Cannabics Pharmaceuticals, Cannabis Biocare, Cannabis Therapeutics, CannAmerica Brands, CannaRoyalty, Canopy Health Innovations, Capna Intellectual, Capnia, Cardio3 Biosciences Asia Holdings, Casebia Therapeutics, Catapult Therapy TCR, CB2 Therapeutics, CBDerma Technology, CBDistribution, Cedar Gate Technologies, CeGaT, Cell Therapy Catapult, Celyad, Centauri Therapeutics, Centene, Center for Genetic Engineering and Biotechnology (Cuba), Centre for Commercialization of Regenerative Medicine (CCRM), Centro de Inmunolgía Molecular, Cerevel Therapeutics, Cesca Therapeutics, Chan Soon-Shiong Institute of Molecular Medicine, ChemAxon, Children's Medical Research Institute, Chimera Biotec, China-Israel Biological Technology, China-Singapore Guangzhou Knowledge City, China Isotope And Radiation, Chinese Academy of Science, Chinese Future Industry Investment Fund, Chongqing PSK-Health Sci-tech Development, Cincinnati Children’s Hospital Medical Center, City of Hope, CJ CheilJedang, ClearPath, Cloaked Therapeutics, Co-Diagnostics, Cohen Veterans Bioscience, Cold Spring Harbor, Colibri Heart Valve, Collagen Solutions Plc, Columbus Venture Partners, Concentrics Research, Consortium AI, Corestone Biosciences, Cornerstone Animal Health, Corning, Covenant Animal Health Partners, Cre8ive, CRISPR Therapeutics, CureCell, Cyclica, CytoBioscience, Cytotheryx, Cytovant Sciences, Daewoong Pharmaceutical, Dance Biopharm, Dasman Diabetes Institute, David Snow, Deerfield Management, DemeRx, Demetra, Denka, Denka-KEW Genomics, DepYmed, DIAN Diagnostics, Diavax Biosciences, Dixi, Dizal Pharmaceutical, DolCas-Tenshi Bioceuticals, DolCas Biotech, Dona Blanca, Dongbao, Dr. Walter Bell, Duke-NUS Graduate Medical School Singapore, Eastar Industries, Eastern Capital, Easton Pharmaceuticals, eCardio Diagnostics, Eddingpharm, Eden BioCell, Elanix Biotechnologies, Elevar Therapeutics, Eli Lilly, EMD Millipore, EMD Serono, Emergence Therapeutics, EmoCellix, Emory University, Emosis, Enigma Diagnostics, Enova Illumination, Entheogenix Biosciences, ERS Genomics, Evotec, ExCellThera, Exemplar Genetics, Facebook, Faes Farma, Faxian Therapeutics, Fedecore, Fedora Pharmaceuticals, FerGene, Ferring Pharmaceuticals, FJ Pharma, Flexpoint Ford, Flow Pharma, Fonterra, Food and Drug Administration (FDA), FORMA Therapeutics, Fortress Biotech, Fosun Pharmaceutical, FoxBio, Fox Chase Cancer Center, Fraunhofer Institute for Microelectronic Circuits and Systems, Frazier Healthcare Ventures, Fresenius Kabi Pharmaceuticals, Frontage Laboratories, FSD Pharma, Futura Medical, Fuzionaire Diagnostics, Fuzionaire Radioisotope Technologies, G-treeBNT, Galectin Sciences, Galectin Therapeutics, Galvani Bioelectronics, Gauss Surgical, Genentech, Gene Therapy Research Institution, Genetic Technologies, Genevant Sciences, Genome Institute of Singapore, Genomix Scientific, Gentag, GeoVax, German Research Center for Artificial Intelligence, Gerresheimer, GHO Capital, Ginkgo BioWorks, GlaxoSmithKline, GL Brands, GLG Pharma, Global Canna Labs, Global Drug Development Centre (GDCC) China, GNC, Great Bay Bio, Grenco Science, Grow Biotech, Grupo Natac, GTCR Golder Rauner, GtreeBNT, Guangzhou Boji Medical Biotechnological, Guangzhou Xiangxue Pharmaceutical, Hainan Savy Akers Biosciences, Hainan Savy Investment Management, HardTech Labs, Harvard University, HealthBanks Biotech, HealthMed Services, Hefei Sageland Biotechnology, Heidelberg Engineering, Heidelberg Pharma, Helomics, Hepregen, Herman Holdings, Hi-Tech Pharmaceuticals, HiFiBio, HighRes Biosolutions, Hillhouse Capital Group, Histogen, Histogen Oncology, Hollister Biosciences, Horizon Discovery, Horizon Pharma plc, Huakang Biomedical, HUYA Bioscience, hVIVO, I-Bridge Capital, iBio, ICAN, Icon, ImaginAb, IMD Companies, ImmuneCyte Life Sciences, ImmuneOncia, iMPak Health, Imperial College London, Imperial Innovations, Imutex, Inception 5, Inception Sciences, Indegene Lifesystems, Index Ventures, India Colorada, Infectious Disease Research Institute (IDRI), Infinity Group, Innoplexus, Innovation Network Corporation, Innovative Immunotherapy Alliance, Insilico, Institute for Research in Immunology and Cancer – Commercialization of Research, Institut Pasteur, Institut Pasteur of Shanghai at the Chinese Academy of Sciences, Intercontinental Marketing, International Research Center on Cannabis and Mental Health, International Vitamin, Intuitive Surgical, Invictus MD Stategies, Invitrocue, InvivoCue, INVO Bioscience, IPS Specials, JAGUAHR Therapeutics, Japan Medical Isotope Technology Development, JAYEX Technology, Johnson & Johnson, Johnson & Johnson Innovation, Joint Venture Partner Group, Juvenescence, Jvion, Kaiima Bio-Agritech, Kangmei Pharma, Kanyos, Kastle Therapeutics, Keensight Capital, Kennedy Health System, KEW, Kineta, Kineta RLB, Kite Pharma, KLOX Technologies, KPI Therapeutics, Kubota Pharmaceutical, Kurma Life Sciences Partners, Kuwait Life Sciences, Lab1636, LabCentral, La Jolla Institute for Allergy & Immunology, Lenus Therapeutics, LEO Pharma, LifeArc, Life Chemicals, Lifestyle Delivery Systems, LifeTech Scientific, Liht Cannabis, Lineage Cell Therapeutics, Living Proof, Lonza, Lupin, Lupus Foundation of America (LFA), Lyndra Therapeutics, Lyphe Group, Lyra Health, Maccura Biotechnology, MAGiQ Therapeutics, Magnum Cell Therapies, Malaghan Institute, MapKure, Massachusetts General Hospital, MaSTherCell, Mayo Clinic, McKesson, McLean Hospital, Medcolcanna Organics, Medesole Healthcare and Trading, Medesole INVO Bioscience, Medical Marketing Economics, Medicrea, MedinCell, Medipal Holdings, Medisun International, Medpace, MedQuest, Medybloom, Medytox, Meiji Seika, MemorialCare Health System, Merck and Co, Merck KGaA, MicroPort Scientific, MicroPort Sorin CRM (Shanghai), Milestone Advanced Cosmetic Systems, Milestone China, Milestone Scientific, Mimi’s Rock, Mino Labs, Miraca, Mobidiag, Molnlycke Health Care, Mota Ventures, Motion Medical, MPI Research, MTP Material, Mundimed, MVI Health, Mylan Laboratories, Mylan Pharmaceuticals, NacuGen Therapeutics, Nakashima, NantWorks, Napa Therapeutics, Natac Solutions, National Green Biomed, National Institutes of Health, National Surgical Care, Navidea Biopharmaceuticals, Nemaura Medical, Neopharma, Neostell, Neovacs, NephCure Kidney International, Neptune Technologies & Bioressources, NetraMark, NetraPharma, NetScientific, NewCanna Hub, New York Genome Center (NYGC), NHS Bio, Nicox, Nikkol, Nisarga Biotech, Nizo, North Mississippi Health Services, Not-So-Gentle Tea Company, Novaliq, Novant Health, Novartis, Noviosense, Novocam Medical Innovations, Novogene, NuAxon BioScience, Nuritas, Nutra Manufacturing, OG Laboratories, Ohr Pharmaceuticals, OncoQuest, OncoStatyx, OncoVent, Oncurious, One BioMed, Onegevity, One World Pharma, Optasia Medical, OptiBiotix, Orgenesis, Oxford MEstar, Oxford Sciences Innovation, Palantir, PentixaPharm, Penumbra, Perennial, PerkinElmer, Pfizer, PharmaCielo, PharmaPraxis, Phathom Pharmaceuticals, Philips, Pinnacle Hill, Pittsburgh Life Sciences Greenhouse, Pivot Pharmaceuticals, PlantForm, Pluristem Therapeutics, Polytherics, Portage Glasgow, Portage Pharmaceuticals, Poseidon Innovation, PPD, PRA Health Sciences, Premier Biomedical, Prenetics, Preventice, Preventice Inc, Profarma, ProMedica Health System, Prometic Life Sciences, Promimic, Provectus Biopharmaceuticals, Provision Asia, Purdue Pharma, Q2 Solutions, Qiagen, Q Therapeutics, Quantum Surgical, Quest Diagnostics, Quintiles, R-NAV, Radient Technologies, RadNet, Rafarma Pharmaceuticals, Raizen Energia, Rare Expertise, RavenQuest BioMed, Regenerx, Reliance Animal Health Partners, RenalytixAI, RENX AI Labs, ReproCell, Resmed, Respiratory Motion, Revive Therapeutics, Rheumco, RLB Holdings, Rochal Industries, Roche, Roche Diagnostics, Rock-One International, Roivant Sciences, Romulus Titan, Roswell Park Cancer Institute, Royal Philips Electronics, RSV, Samsung Bioepis, Sanara Ventures, Sanofi, Sanuwave Health, Sartorius, SAVSU Technologies, SBH Sciences, SBI Capital Markets, Scentryphar, Schrodinger, Sciex, Scintomics, Scohia Pharma, SCOUT, Seegene, SEEK, SEngine Precision Medicine, Sensyne Health, Shanghai Chonghe Marine Industry, Shanghai Hi-Tech Nutraceuticals, Shanghai Pharmaceutical, Shanghai Pharmaceuticals Greater Health Online Company, Shenzhen Arimab Biopharmaceuticals, Shenzhen Hepalink Pharmaceutical, Shenzhen Neptunus Interlong Bio-Technique, Shenzhen Yunma Biotechnology, Shimadzu Scientific Instruments, Shin Nippon Biomedical Laboratories, Sinovant Sciences, Sirona Biochem, Sixense Enterprises, SkinBiotix, Skyline Medical, Smart Medicines GMP, Solaris, Soleno Therapeutics, Sonic Healthcare, Sorin Group, Sorrento Therapeutics, Sosei, Southern Cross University, SpringWorks Therapeutics, Sproutly, Stanford University, Starbuds, STATKING Clinical Services, Steep Hills Labs, Stellar Biotechnologies, StemoniX, Stonehaven Incubate, SunGen, SV Life Science, Synbiotics, Syneos Health, Synlogic, Sysmex, Tactical Relief, TaiRx, TaiRx US, Takeda Pharmaceutical, Talem Therapeutics, Tauriga Sciences, TechCare, Technology Acceleration Partners, Tecres, Teijin, Teijin Nakashima Medical, Tenshi Kaizen, Tessa Therapeutics, Tetra Bio-Pharma, Teva Pharmaceutical Industries, The Alchemists Kitchen, Thermo Fisher Scientific, ThermoGenesis, Thorne Research, ThromboGenics, Tianjin Institute of Pharmaceutical Research, Tianyin Pharmaceutical, TIPR-HUYA Advancing Innovative Medicines, Titian Software, TNK Therapeutics, Todos Medical, Tonghua Dongbao Pharma, TranScrip, Translational Medicine Accelerator, Trellis Growing Solutions, Trellis Growing Systems, TriArm Therapeutics, Tririver Capital, Triventis, Trivitron Healthcare, Truffle Capital, UBC, UCL Business, UK Government, University City Science Center, University College London, University of California, San Diego, University of Cambridge, University of Glasgow, University of Manchester, University of Maryland, University of Michigan, University of Northern Colorado, University of Oxford, University of Pittsburgh, University of Wisconsin, Valeant Pharmaceuticals, Valorem Surgical, Valorem Surgical AP, Vancouver Prostate Centre, Vapium, Vasomedical, Veeva Systems, Velocity Pharmaceutical Development, Venus Medtech, Venus Remedies, Verily, Versant Ventures, Versartis, Vertical Companies, ViaMune, VIB, Victa Biotherapeutics, Vifor Pharma, Viralgen, VISEN Pharmaceuticals, Vitesse Biologics, Vivo Ventures, VSK Medical, Vyaire Medical, Vyripharm, Walgreens, WardMM, Washington University in St Louis, Wexford Science & Technology, Wilson Wolf, Wirthlin-Denton, Wize Pharma, World Class Extractions, Wuxi Apptec Laboratory Services, Wylde, X-chem, YL Biologics, Yongyi Biotechnology, Yongyi Hi-Tech Nutraceuticals, Yoshindo, Yuhan Corporation, YuYang DNU, Zhaotai Group, Zhejiang Jiuzhou Pharmaceutical, Zhongxie Pharma, Ziopharm Oncology